Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.
Viral vector-based gene therapies have made great progress to date, and several products that treat rare genetic diseases are commercially available. The clinical pipeline is growing steadily, with the focus turning to more prevalent indications targeted using primarily recombinant AAVs (rAAVs). Rising demand for rAAV quantities is driving the need for robust process development and large-scale manufacturing capabilities.
In this webinar, OBiO Technology will highlight their process development strategies to scale up a transient transfection-based AAV production process from 15 to 1,000L in a single-use, stirred-tank bioreactor.